These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 38709912

  • 1. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.
    Fu W, Liu L, Tong S.
    Thorac Cancer; 2024 Jun; 15(17):1357-1368. PubMed ID: 38709912
    [Abstract] [Full Text] [Related]

  • 2. METTL3-mediated m6A modification of CDCA7 mRNA promotes COAD progression.
    Hua M, Zhai X, Chen Y, Yin D.
    Pathol Res Pract; 2024 Aug; 260():155437. PubMed ID: 38959625
    [Abstract] [Full Text] [Related]

  • 3. METTL3/IGF2BP1 influences the development of non-small-cell lung cancer by mediating m6A methylation modification of TRPV1.
    Bai W, Xiao G, Xie G, Chen Z, Xu X, Zeng J, Xie J.
    Thorac Cancer; 2024 Sep; 15(26):1871-1881. PubMed ID: 39090761
    [Abstract] [Full Text] [Related]

  • 4. M6A-induced transcription factor IRF5 contributes to the progression of cervical cancer by upregulating PPP6C.
    Hou PX, Fan Q, Zhang Q, Liu JJ, Wu Q.
    Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13868. PubMed ID: 38745265
    [Abstract] [Full Text] [Related]

  • 5. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.
    He P, Liu X, Yu G, Wang Y, Wang S, Liu J, An Y.
    Mol Cell Biochem; 2024 Jul; 479(7):1707-1720. PubMed ID: 38822192
    [Abstract] [Full Text] [Related]

  • 6. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM, Qi FF, Wang J, Duan YY, Zhao LL, Wang YD, Zhang TC, Liao XH.
    Int J Mol Sci; 2022 Jun 09; 23(12):. PubMed ID: 35742899
    [Abstract] [Full Text] [Related]

  • 7. Circ_0027791 contributes to the growth and immune evasion of hepatocellular carcinoma via the miR-496/programmed cell death ligand 1 axis in an m6A-dependent manner.
    Yu F, Fang P, Fang Y, Chen D.
    Environ Toxicol; 2024 Jun 09; 39(6):3721-3733. PubMed ID: 38546290
    [Abstract] [Full Text] [Related]

  • 8. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer.
    Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W, Guo W, Wu X, Pu C, Hu X, Li Z, Yao M, Luo D, Xu X.
    Mol Cancer; 2022 Feb 23; 21(1):60. PubMed ID: 35197058
    [Abstract] [Full Text] [Related]

  • 9. METTL3 and IGF2BP1-Mediated m6A Modification of ZHX2 Promotes Tumor Property of Renal Cell Carcinoma.
    Xiao B, Li Y, Yang Y, Chen C, Gong S, Li H, Yao Q, Wang L.
    Kidney Blood Press Res; 2024 Feb 23; 49(1):787-798. PubMed ID: 39159608
    [Abstract] [Full Text] [Related]

  • 10. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2019 Dec 09; 12(1):135. PubMed ID: 31818312
    [Abstract] [Full Text] [Related]

  • 11. METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1.
    Song D, Wang Q, Yan Z, Su M, Zhang H, Shi L, Fan Y, Zhang Q, Yang H, Zhang D, Liu Q.
    Biol Direct; 2024 Jun 07; 19(1):44. PubMed ID: 38849910
    [Abstract] [Full Text] [Related]

  • 12. Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3.
    Zhang Y, Liu X, Yu M, Xu M, Xiao Y, Ma W, Huang L, Li X, Ye X.
    Life Sci; 2020 Nov 01; 260():118413. PubMed ID: 32926933
    [Abstract] [Full Text] [Related]

  • 13. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J, Xie H, Ying Y, Chen H, Yan H, He L, Xu M, Xu X, Liang Z, Liu B, Wang X, Zheng X, Xie L.
    Mol Cancer; 2020 Oct 29; 19(1):152. PubMed ID: 33121495
    [Abstract] [Full Text] [Related]

  • 14. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
    Yi J, Peng F, Zhao J, Gong X.
    Sci Rep; 2023 Oct 12; 13(1):17292. PubMed ID: 37828232
    [Abstract] [Full Text] [Related]

  • 15. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
    Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z, Zhao G.
    Mol Cancer; 2019 Oct 13; 18(1):142. PubMed ID: 31607270
    [Abstract] [Full Text] [Related]

  • 16. Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6.
    Xu M, Ren L, Fan J, Huang L, Zhou L, Li X, Ye X.
    Life Sci; 2022 Feb 01; 290():120266. PubMed ID: 34968467
    [Abstract] [Full Text] [Related]

  • 17. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
    Chen WW, Qi JW, Hang Y, Wu JX, Zhou XX, Chen JZ, Wang J, Wang HH.
    Eur Rev Med Pharmacol Sci; 2020 Apr 01; 24(8):4263-4270. PubMed ID: 32373962
    [Abstract] [Full Text] [Related]

  • 18. Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
    Li S, Lu X, Zheng D, Chen W, Li Y, Li F.
    J Cancer Res Clin Oncol; 2022 Dec 01; 148(12):3485-3499. PubMed ID: 35907010
    [Abstract] [Full Text] [Related]

  • 19. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
    Meng QZ, Cong CH, Li XJ, Zhu F, Zhao X, Chen FW.
    Eur Rev Med Pharmacol Sci; 2020 Apr 01; 24(8):4328-4336. PubMed ID: 32373970
    [Abstract] [Full Text] [Related]

  • 20. Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo.
    Zhao Y, Jing Z, Lv J, Zhang Z, Lin J, Cao X, Zhao Z, Liu P, Mao W.
    Biomed Pharmacother; 2017 Nov 01; 95():18-24. PubMed ID: 28826092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.